This invention has benefit over other methods since it directly quantitates the mAb without the need for interaction with the antigen. By monitoring tryptic peptides from the unique variable regions of the therapeutic mAb and comparing them to the constant regions of a non-human antibody added as an internal standard, the mAb can be measured. This method is superior to other methods using tryptic peptide since the additon of the non-human antibody gives superior accuracy.
Quantifying Monoclonal Therapeutic Antibodies by LC-MS/MSTechnology #2013-206
Questions about this technology? Ask a Technology Manager